APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Angiogenesis Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Angiogenesis Inhibitors Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchCancer Angiogenesis Inhibitors Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Angiogenesis Inhibitors Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cancer Angiogenesis Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Angiogenesis Inhibitors Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Angiogenesis Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Cancer Angiogenesis Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Angiogenesis Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Angiogenesis Inhibitors market include Novartis, Neumedicines, Marsala Biotech, Mabtech, Levolta Pharmaceuticals, Kyowa Hakko Kirin, Intas Pharmaceuticals, ImClone Systems and Hetero Drugs, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Angiogenesis Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Angiogenesis Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Angiogenesis Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Angiogenesis Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Angiogenesis Inhibitors Segment by Company

Novartis

Neumedicines

Marsala Biotech

Mabtech

Levolta Pharmaceuticals

Kyowa Hakko Kirin

Intas Pharmaceuticals

ImClone Systems

Hetero Drugs

Genexine

Genentech

Fuji Film Kyowa Kirin Biologics

Five Prime Therapeutics

Cancer Angiogenesis Inhibitors Segment by Type

Oncogene Targeted Therapy

Matrix Degrading & Remodeling Targeted Therapy

VEGF Targeted Therapy

FGF Targeted Therapies

Others

Cancer Angiogenesis Inhibitors Segment by Application

Ocular Neovascularization

Interferon Alpha-2α

Cancer

Cancer Angiogenesis Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Angiogenesis Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Angiogenesis Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Angiogenesis Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Angiogenesis Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Angiogenesis Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Angiogenesis Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Angiogenesis Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Angiogenesis Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Angiogenesis Inhibitors industry.

Chapter 3: Detailed analysis of Cancer Angiogenesis Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Angiogenesis Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Angiogenesis Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Angiogenesis Inhibitors Industry Trends Table 2. Cancer Angiogenesis Inhibitors Industry Drivers Table 3. Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges Table 4. Cancer Angiogenesis Inhibitors Industry Restraints Table 5. Global Cancer Angiogenesis Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Angiogenesis Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Cancer Angiogenesis Inhibitors Sales Volume by Company (k units) & (2021-2026) Table 8. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Angiogenesis Inhibitors Average Price (US$/unit) of Company (2021-2026) Table 10. Global Cancer Angiogenesis Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Angiogenesis Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Angiogenesis Inhibitors Company, Product Type & Application Table 13. Global Cancer Angiogenesis Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Angiogenesis Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oncogene Targeted Therapy Table 18. Significant Companies of Matrix Degrading & Remodeling Targeted Therapy Table 19. Significant Companies of VEGF Targeted Therapy Table 20. Significant Companies of FGF Targeted Therapies Table 21. Significant Companies of Others Table 22. Global Cancer Angiogenesis Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Cancer Angiogenesis Inhibitors Sales Volume by Type (2021-2026) & (k units) Table 24. Global Cancer Angiogenesis Inhibitors Sales Volume by Type (2027-2032) & (k units) Table 25. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Type (2021-2026) Table 26. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Type (2027-2032) Table 27. Global Cancer Angiogenesis Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Cancer Angiogenesis Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Cancer Angiogenesis Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Cancer Angiogenesis Inhibitors Sales Value Share by Type (2021-2026) Table 31. Global Cancer Angiogenesis Inhibitors Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Ocular Neovascularization Table 33. Significant Companies of Interferon Alpha-2α Table 34. Significant Companies of Cancer Table 35. Global Cancer Angiogenesis Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Cancer Angiogenesis Inhibitors Sales Volume by Application (2021-2026) & (k units) Table 37. Global Cancer Angiogenesis Inhibitors Sales Volume by Application (2027-2032) & (k units) Table 38. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2021-2026) Table 39. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2027-2032) Table 40. Global Cancer Angiogenesis Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Cancer Angiogenesis Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Cancer Angiogenesis Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Cancer Angiogenesis Inhibitors Sales Value Share by Application (2021-2026) Table 44. Global Cancer Angiogenesis Inhibitors Sales Value Share by Application (2027-2032) Table 45. Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2026) & (k units) Table 47. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Cancer Angiogenesis Inhibitors Sales by Region (2027-2032) & (k units) Table 49. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2027-2032) Table 50. Global Cancer Angiogenesis Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Cancer Angiogenesis Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Cancer Angiogenesis Inhibitors Sales Value Share by Region (2021-2026) Table 53. Global Cancer Angiogenesis Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Cancer Angiogenesis Inhibitors Sales Value Share by Region (2027-2032) Table 55. Global Cancer Angiogenesis Inhibitors Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Cancer Angiogenesis Inhibitors Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Cancer Angiogenesis Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Cancer Angiogenesis Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 60. Global Cancer Angiogenesis Inhibitors Sales Market Share by Country (2021-2026) Table 61. Global Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 62. Global Cancer Angiogenesis Inhibitors Sales Market Share by Country (2027-2032) Table 63. Global Cancer Angiogenesis Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Cancer Angiogenesis Inhibitors Sales Value Market Share by Country (2021-2026) Table 65. Global Cancer Angiogenesis Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Cancer Angiogenesis Inhibitors Sales Value Market Share by Country (2027-2032) Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Novartis Cancer Angiogenesis Inhibitors Product Portfolio Table 71. Novartis Recent Development Table 72. Neumedicines Company Information Table 73. Neumedicines Business Overview Table 74. Neumedicines Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio Table 76. Neumedicines Recent Development Table 77. Marsala Biotech Company Information Table 78. Marsala Biotech Business Overview Table 79. Marsala Biotech Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio Table 81. Marsala Biotech Recent Development Table 82. Mabtech Company Information Table 83. Mabtech Business Overview Table 84. Mabtech Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Mabtech Cancer Angiogenesis Inhibitors Product Portfolio Table 86. Mabtech Recent Development Table 87. Levolta Pharmaceuticals Company Information Table 88. Levolta Pharmaceuticals Business Overview Table 89. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio Table 91. Levolta Pharmaceuticals Recent Development Table 92. Kyowa Hakko Kirin Company Information Table 93. Kyowa Hakko Kirin Business Overview Table 94. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio Table 96. Kyowa Hakko Kirin Recent Development Table 97. Intas Pharmaceuticals Company Information Table 98. Intas Pharmaceuticals Business Overview Table 99. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio Table 101. Intas Pharmaceuticals Recent Development Table 102. ImClone Systems Company Information Table 103. ImClone Systems Business Overview Table 104. ImClone Systems Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio Table 106. ImClone Systems Recent Development Table 107. Hetero Drugs Company Information Table 108. Hetero Drugs Business Overview Table 109. Hetero Drugs Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio Table 111. Hetero Drugs Recent Development Table 112. Genexine Company Information Table 113. Genexine Business Overview Table 114. Genexine Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Genexine Cancer Angiogenesis Inhibitors Product Portfolio Table 116. Genexine Recent Development Table 117. Genentech Company Information Table 118. Genentech Business Overview Table 119. Genentech Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Genentech Cancer Angiogenesis Inhibitors Product Portfolio Table 121. Genentech Recent Development Table 122. Fuji Film Kyowa Kirin Biologics Company Information Table 123. Fuji Film Kyowa Kirin Biologics Business Overview Table 124. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio Table 126. Fuji Film Kyowa Kirin Biologics Recent Development Table 127. Five Prime Therapeutics Company Information Table 128. Five Prime Therapeutics Business Overview Table 129. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio Table 131. Five Prime Therapeutics Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Cancer Angiogenesis Inhibitors Distributors List Table 135. Cancer Angiogenesis Inhibitors Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Cancer Angiogenesis Inhibitors Product Image Figure 2. Global Cancer Angiogenesis Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Angiogenesis Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Angiogenesis Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Cancer Angiogenesis Inhibitors Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Cancer Angiogenesis Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oncogene Targeted Therapy Image Figure 10. Matrix Degrading & Remodeling Targeted Therapy Image Figure 11. VEGF Targeted Therapy Image Figure 12. FGF Targeted Therapies Image Figure 13. Others Image Figure 14. Global Cancer Angiogenesis Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Cancer Angiogenesis Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Type (2021-2032) Figure 17. Global Cancer Angiogenesis Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cancer Angiogenesis Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Cancer Angiogenesis Inhibitors Sales Value Share by Type (2021-2032) Figure 20. Ocular Neovascularization Image Figure 21. Interferon Alpha-2α Image Figure 22. Cancer Image Figure 23. Global Cancer Angiogenesis Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Cancer Angiogenesis Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2021-2032) Figure 26. Global Cancer Angiogenesis Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Cancer Angiogenesis Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Cancer Angiogenesis Inhibitors Sales Value Share by Application (2021-2032) Figure 29. Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Cancer Angiogenesis Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Cancer Angiogenesis Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Cancer Angiogenesis Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. North America Cancer Angiogenesis Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Cancer Angiogenesis Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Cancer Angiogenesis Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Cancer Angiogenesis Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 40. South America Cancer Angiogenesis Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Cancer Angiogenesis Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Cancer Angiogenesis Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Cancer Angiogenesis Inhibitors Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Cancer Angiogenesis Inhibitors Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Oncogene Targeted Therapy
  • Matrix Degrading & Remodeling Targeted Therapy
  • VEGF Targeted Therapy
  • FGF Targeted Therapies
  • Others
Applications
  • Ocular Neovascularization
  • Interferon Alpha-2α
  • Cancer
Companies covered
  • Novartis
  • Neumedicines
  • Marsala Biotech
  • Mabtech
  • Levolta Pharmaceuticals
  • Kyowa Hakko Kirin
  • Intas Pharmaceuticals
  • ImClone Systems
  • Hetero Drugs
  • Genexine
  • Genentech
  • Fuji Film Kyowa Kirin Biologics
  • Five Prime Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Angiogenesis Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Angiogenesis Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Angiogenesis Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Angiogenesis Inhibitors Market Dynamics
  1. 2.1 Cancer Angiogenesis Inhibitors Industry Trends
  2. 2.2 Cancer Angiogenesis Inhibitors Industry Drivers
  3. 2.3 Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges
  4. 2.4 Cancer Angiogenesis Inhibitors Industry Restraints
3 Cancer Angiogenesis Inhibitors Market by Company
  1. 3.1 Global Cancer Angiogenesis Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Angiogenesis Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Angiogenesis Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Angiogenesis Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Angiogenesis Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Cancer Angiogenesis Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Angiogenesis Inhibitors Company Product Type and Application
  8. 3.8 Global Cancer Angiogenesis Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Angiogenesis Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Angiogenesis Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Angiogenesis Inhibitors Market by Type
  1. 4.1 Cancer Angiogenesis Inhibitors Type Introduction
  2. 4.1.1 Oncogene Targeted Therapy
  3. 4.1.2 Matrix Degrading & Remodeling Targeted Therapy
  4. 4.1.3 VEGF Targeted Therapy
  5. 4.1.4 FGF Targeted Therapies
  6. 4.1.5 Others
  7. 4.2 Global Cancer Angiogenesis Inhibitors Sales Volume by Type
  8. 4.2.1 Global Cancer Angiogenesis Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Cancer Angiogenesis Inhibitors Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Cancer Angiogenesis Inhibitors Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Cancer Angiogenesis Inhibitors Sales Value by Type
  12. 4.3.1 Global Cancer Angiogenesis Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Cancer Angiogenesis Inhibitors Sales Value by Type (2021-2032)
  14. 4.3.3 Global Cancer Angiogenesis Inhibitors Sales Value Share by Type (2021-2032)
5 Cancer Angiogenesis Inhibitors Market by Application
  1. 5.1 Cancer Angiogenesis Inhibitors Application Introduction
  2. 5.1.1 Ocular Neovascularization
  3. 5.1.2 Interferon Alpha-2α
  4. 5.1.3 Cancer
  5. 5.2 Global Cancer Angiogenesis Inhibitors Sales Volume by Application
  6. 5.2.1 Global Cancer Angiogenesis Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Angiogenesis Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cancer Angiogenesis Inhibitors Sales Value by Application
  10. 5.3.1 Global Cancer Angiogenesis Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Angiogenesis Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cancer Angiogenesis Inhibitors Sales Value Share by Application (2021-2032)
6 Cancer Angiogenesis Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Angiogenesis Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Angiogenesis Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Cancer Angiogenesis Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Angiogenesis Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Angiogenesis Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Angiogenesis Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Angiogenesis Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Angiogenesis Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Angiogenesis Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Angiogenesis Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Angiogenesis Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Angiogenesis Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Angiogenesis Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Angiogenesis Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Angiogenesis Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Angiogenesis Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Angiogenesis Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Cancer Angiogenesis Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Angiogenesis Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Angiogenesis Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Angiogenesis Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Angiogenesis Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Cancer Angiogenesis Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Angiogenesis Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Angiogenesis Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Angiogenesis Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Angiogenesis Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Angiogenesis Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Cancer Angiogenesis Inhibitors Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Neumedicines
  8. 8.2.1 Neumedicines Company Information
  9. 8.2.2 Neumedicines Business Overview
  10. 8.2.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio
  12. 8.2.5 Neumedicines Recent Developments
  13. 8.3 Marsala Biotech
  14. 8.3.1 Marsala Biotech Company Information
  15. 8.3.2 Marsala Biotech Business Overview
  16. 8.3.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio
  18. 8.3.5 Marsala Biotech Recent Developments
  19. 8.4 Mabtech
  20. 8.4.1 Mabtech Company Information
  21. 8.4.2 Mabtech Business Overview
  22. 8.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mabtech Cancer Angiogenesis Inhibitors Product Portfolio
  24. 8.4.5 Mabtech Recent Developments
  25. 8.5 Levolta Pharmaceuticals
  26. 8.5.1 Levolta Pharmaceuticals Company Information
  27. 8.5.2 Levolta Pharmaceuticals Business Overview
  28. 8.5.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
  30. 8.5.5 Levolta Pharmaceuticals Recent Developments
  31. 8.6 Kyowa Hakko Kirin
  32. 8.6.1 Kyowa Hakko Kirin Company Information
  33. 8.6.2 Kyowa Hakko Kirin Business Overview
  34. 8.6.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio
  36. 8.6.5 Kyowa Hakko Kirin Recent Developments
  37. 8.7 Intas Pharmaceuticals
  38. 8.7.1 Intas Pharmaceuticals Company Information
  39. 8.7.2 Intas Pharmaceuticals Business Overview
  40. 8.7.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
  42. 8.7.5 Intas Pharmaceuticals Recent Developments
  43. 8.8 ImClone Systems
  44. 8.8.1 ImClone Systems Company Information
  45. 8.8.2 ImClone Systems Business Overview
  46. 8.8.3 ImClone Systems Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio
  48. 8.8.5 ImClone Systems Recent Developments
  49. 8.9 Hetero Drugs
  50. 8.9.1 Hetero Drugs Company Information
  51. 8.9.2 Hetero Drugs Business Overview
  52. 8.9.3 Hetero Drugs Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio
  54. 8.9.5 Hetero Drugs Recent Developments
  55. 8.10 Genexine
  56. 8.10.1 Genexine Company Information
  57. 8.10.2 Genexine Business Overview
  58. 8.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Genexine Cancer Angiogenesis Inhibitors Product Portfolio
  60. 8.10.5 Genexine Recent Developments
  61. 8.11 Genentech
  62. 8.11.1 Genentech Company Information
  63. 8.11.2 Genentech Business Overview
  64. 8.11.3 Genentech Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Genentech Cancer Angiogenesis Inhibitors Product Portfolio
  66. 8.11.5 Genentech Recent Developments
  67. 8.12 Fuji Film Kyowa Kirin Biologics
  68. 8.12.1 Fuji Film Kyowa Kirin Biologics Company Information
  69. 8.12.2 Fuji Film Kyowa Kirin Biologics Business Overview
  70. 8.12.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio
  72. 8.12.5 Fuji Film Kyowa Kirin Biologics Recent Developments
  73. 8.13 Five Prime Therapeutics
  74. 8.13.1 Five Prime Therapeutics Company Information
  75. 8.13.2 Five Prime Therapeutics Business Overview
  76. 8.13.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio
  78. 8.13.5 Five Prime Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Angiogenesis Inhibitors Value Chain Analysis
  2. 9.1.1 Cancer Angiogenesis Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Angiogenesis Inhibitors Sales Mode & Process
  6. 9.2 Cancer Angiogenesis Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Angiogenesis Inhibitors Distributors
  9. 9.2.3 Cancer Angiogenesis Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst